Systems biology and modeling in neuroblastoma: practicalities and perspectives

References

• Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet369(9579), 2106–2120 (2007).
   PubMed Web of Science ®Google Scholar
• Castleberry RP. Neuroblastoma. Eur. J. Cancer33(9), 1430–1437 (1997).
   PubMedGoogle Scholar
• Grimmer MR, Weiss WA. Childhood tumors of the nervous system as disorders of normal development. Curr. Opin. Pediatr.18(6), 634–638 (2006).
   PubMedGoogle Scholar
• Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat. Rev. Cancer3(3), 203–216 (2003).
   PubMed Web of Science ®Google Scholar
• Tanaka T, Lehara T, Sugimoto T et al. Diversity in neuroblastomas and discrimination of the risk to progress. Cancer Lett.228(1–2), 267–270 (2005).
   PubMedGoogle Scholar
• D’Angio GJ, AE Evans, CE Koop. Special pattern of widespread neuroblastoma with a favourable prognosis. Lancet1(7708), 1046–1049 (1971).
   PubMed Web of Science ®Google Scholar
• Monclair T, Brodeur GM, Ambros PF et al. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J. Clin. Oncol.27(2), 298–303 (2009).
   PubMed Web of Science ®Google Scholar
• Brodeur GM, Pritchard J, Berthold F et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J. Clin. Oncol.11(8), 1466–1477 (1993).
   PubMed Web of Science ®Google Scholar
• Shimada H, Chatten J, Newton WA Jr et al. Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J. Natl Cancer Inst.73(2), 405–416 (1984).
   PubMed Web of Science ®Google Scholar
• Shimada H, Ambros IM, Dehner LP, Hata J, Joshi W, Roald B. Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee. Cancer86(2), 349–363 (1999).
   PubMed Web of Science ®Google Scholar
• London WB, Castleberry RP, Matthay KK et al. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children’s Oncology Group. J. Clin. Oncol.23(27), 6459–6465 (2005).
   PubMed Web of Science ®Google Scholar
• Riley RD, Heney D, Jones DR et al. A systematic review of molecular and biological tumor markers in neuroblastoma. Clin. Cancer Res.10(1 Pt 1), 4–12 (2004).
   PubMed Web of Science ®Google Scholar
• Cohn SL, Pearson AD, London WB et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J. Clin. Oncol.27(2), 289–297 (2009).
   PubMed Web of Science ®Google Scholar
• Seeger RC, Brodeur GM, Sather H et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N. Engl. J. Med.313(18), 1111–1116 (1985).
   PubMed Web of Science ®Google Scholar
• Bagatell R, Rumcheva P, London WB et al. Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumor cell ploidy. J. Clin. Oncol.23(34), 8819–8827 (2005).
   PubMedGoogle Scholar
• Lehara T, Hosoi H, Akazawa K et al.MYCN gene amplification is a powerful prognostic factor even in infantile neuroblastoma detected by mass screening. Br. J. Cancer94(10), 1510–1515 (2006).
   PubMedGoogle Scholar
• Kaneko Y, Knudson AG. Mechanism and relevance of ploidy in neuroblastoma. Genes Chromosomes Cancer29(2), 89–95 (2000).
   PubMed Web of Science ®Google Scholar
• Spitz R, Betts DR, Simon T et al. Favorable outcome of triploid neuroblastomas: a contribution to the special oncogenesis of neuroblastoma. Cancer Genet. Cytogenet.167(1), 51–56 (2006).
   PubMedGoogle Scholar
• Stallings RL, Carty P McArdle L et al. Molecular cytogenetic analysis of recurrent unbalanced t(11;17) in neuroblastoma. Cancer Genet. Cytogenet.154(1), 44–51 (2004).
   PubMedGoogle Scholar
• Martinsson T, Sjöberg RM, Hedborg F, Kogner P. Deletion of chromosome 1p loci and microsatellite instability in neuroblastomas analyzed with short-tandem repeat polymorphisms. Cancer Res.55(23), 5681–5686 (1995).
   PubMedGoogle Scholar
• Bown N, Cotterill S, Lastowska M et al. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N. Engl. J. Med.340(25), 1954–1961 (1999).
   PubMed Web of Science ®Google Scholar
• Caren H, Abel F, Kogner P, Martinsson T. High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours. Biochem. J.416(2), 153–159 (2008).
   PubMed Web of Science ®Google Scholar
• Diskin SJ, Hou C, Glessner JT et al. Copy number variation at 1q21.1 associated with neuroblastoma. Nature459(7249), 987–991 (2009).
   PubMed Web of Science ®Google Scholar
• Villamon E, Piqueras M, Mackintosh C et al. Comparison of different techniques for the detection of genetic risk-identifying chromosomal gains and losses in neuroblastoma. Virchows Arch.453(1), 47–55 (2008).
   PubMedGoogle Scholar
• Schramm A, Schulte JH, Astrahantseff K et al. Biological effects of TrkA and TrkB receptor signaling in neuroblastoma. Cancer Lett.228(1–2), 143–153 (2005).
   PubMed Web of Science ®Google Scholar
• Taran K, Kobos J, Sitkiewicz A, Sporny S. Estimation of prognostic value of CD44 expression in neuroblastic tumours in children. Folia Neuropathol.45(3), 126–132 (2007).
   PubMedGoogle Scholar
• Castel V, Canete A. A comparison of current neuroblastoma chemotherapeutics. Expert Opin. Pharmacother.5(1), 71–80 (2004).
   PubMed Web of Science ®Google Scholar
• Tonini GP, Pistoia V. Molecularly guided therapy of neuroblastoma: a review of different approaches. Curr. Pharm. Des.12(18), 2303–2317 (2006).
   PubMed Web of Science ®Google Scholar
• Bruggeman FJ, Westerhoff HV. The nature of systems biology. Trends Microbiol.15(1), 45–50 (2007).
   PubMed Web of Science ®Google Scholar
• Han JD. Understanding biological functions through molecular networks. Cell Res.18(2), 224–237 (2008).
   PubMedGoogle Scholar
• Kitano H. Systems biology: a brief overview. Science295(5560), 1662–1664 (2002).
   PubMed Web of Science ®Google Scholar
• Naylor S, Culbertson AW, Valentine SJ, Towards a systems level analysis of health and nutrition. Curr. Opin. Biotechnol.19(2), 100–109 (2008).
   PubMedGoogle Scholar
• Pache RA, Zanzoni A, Naval J, Mas JM, Aloy P. Towards a molecular characterisation of pathological pathways. FEBS Lett.582(8), 1259–1265 (2008).
   PubMed Web of Science ®Google Scholar
• Ho RL, Lieu CA. Systems biology: an evolving approach in drug discovery and development. Drugs R D9(4), 203–216 (2008).
   PubMed Web of Science ®Google Scholar
• Keskin O, Gursoy A, Ma B, Nussinov R. Towards drugs targeting multiple proteins in a systems biology approach. Curr. Top. Med. Chem.7(10), 943–951 (2007).
   PubMedGoogle Scholar
• Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat. Chem. Biol.4(11), 682–690 (2008).
   PubMed Web of Science ®Google Scholar
• Schrattenholz A, Soskic V. What does systems biology mean for drug development? Curr. Med. Chem.15(15), 1520–1528 (2008).
   PubMed Web of Science ®Google Scholar
• Dietel M, Schafer R. Systems pathology – or how to solve the complex problem of predictive pathology. Virchows Arch.453(4), 309–312 (2008).
   PubMedGoogle Scholar
• Nicholson JK. Global systems biology, personalized medicine and molecular epidemiology. Mol. Syst. Biol2, 52 (2006).
   PubMed Web of Science ®Google Scholar
• Feng X, Liu X, Luo Q, Liu BF. Mass spectrometry in systems biology: an overview. Mass Spectrom. Rev.27(6), 635–660 (2008).
   PubMed Web of Science ®Google Scholar
• Teng X, Xiao H. Perspectives of DNA microarray and next-generation DNA sequencing technologies. Sci. China C Life Sci.52(1), 7–16 (2009).
   PubMedGoogle Scholar
• Klipp E, Liebermeister W. Mathematical modeling of intracellular signaling pathways. BMC Neurosci.7(Suppl. 1), S10 (2006).
   Web of Science ®Google Scholar
• Watterson S, Marshall S, Ghazal P. Logic models of pathway biology. Drug Discov. Today13(9–10), 447–456 (2008).
   PubMedGoogle Scholar
• Hecker M, Lambeck S, Toepfer S, van Someren E, Guthke R. Gene regulatory network inference: data integration in dynamic models – a review. Biosystems96(1), 86–103 (2009).
   PubMed Web of Science ®Google Scholar
• van Riel NA. Dynamic modelling and analysis of biochemical networks: mechanism-based models and model-based experiments. Brief Bioinform.7(4), 364–374 (2006).
   PubMed Web of Science ®Google Scholar
• Ghosh D, Poisson LM. “Omics” data and levels of evidence for biomarker discovery. Genomics93(1), 13–16 (2009).
   PubMedGoogle Scholar
• Raffaghello L, Marimpietri D, Pagnan G et al. Anti-GD2 monoclonal antibody immunotherapy: a promising strategy in the prevention of neuroblastoma relapse. Cancer Lett.197(1–2), 205–209 (2003).
   PubMed Web of Science ®Google Scholar
• Taggart D, Dubois S, Matthay KK. Radiolabeled metaiodobenzylguanidine for imaging and therapy of neuroblastoma. Q J Nucl. Med. Mol. Imaging52(4), 403–418 (2008).
   PubMed Web of Science ®Google Scholar
• Brodeur GM. Genetics of embryonal tumours of childhood: retinoblastoma, Wilms’ tumour and neuroblastoma. Cancer Surv.25, 67–99 (1995).
   PubMedGoogle Scholar
• Adhikary S, Eilers M. Transcriptional regulation and transformation by Myc proteins. Nat. Rev. Mol. Cell Biol.6(8), 635–645 (2005).
   PubMed Web of Science ®Google Scholar
• Noble D. Computational models of the heart and their use in assessing the actions of drugs. J. Pharmacol. Sci.107(2), 107–117 (2008).
   PubMed Web of Science ®Google Scholar
• Bizzarri M, Cucina A, Conti F, D’Anselmi F. Beyond the oncogene paradigm: understanding complexity in cancerogenesis. Acta Biotheoretica56(3), 173–196 (2008).
   PubMedGoogle Scholar
• Matthay KK, Villablanca JG, Seeger RC et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children’s Cancer Group. N. Engl. J. Med.341(16), 1165– 1173 (1999).
   PubMed Web of Science ®Google Scholar
• Reynolds CP, Matthay KK, Villablanca JG, Maurer BJ. Retinoid therapy of high-risk neuroblastoma. Cancer Lett.197(1–2), 185–192 (2003).
   PubMed Web of Science ®Google Scholar
• Matthay KK, Reynolds CP, Seeger RC et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children’s oncology group study. J. Clin. Oncol.27(7), 1007–1013 (2009).
   PubMed Web of Science ®Google Scholar
• Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat. Rev. Cancer3(3), 203–216 (2003).
   PubMed Web of Science ®Google Scholar
• Hurlin PJ, Dezfouli S. Functions of myc:max in the control of cell proliferation and tumorigenesis. Int. Rev. Cytol.238, 183–226 (2004).
   PubMed Web of Science ®Google Scholar
• Dang CV, O’Donnell KA, Zeller KI, Nguyen T, Osthus RC, Li F. The c-Myc target gene network. Semin. Cancer Biol.16(4), 253–264 (2006).
   PubMed Web of Science ®Google Scholar
• Alaminos M, Gerald WL, Cheung NK. Prognostic value of MYCN and ID2 overexpression in neuroblastoma. Pediatr. Blood Cancer45(7), 909–915 (2005).
   PubMedGoogle Scholar
• Hermeking H, Rago C, Schuhmacher M et al. Identification of CDK4 as a target of c-MYC. Proc. Natl Acad. Sci. USA97(5), 2229–2234 (2000).
   PubMed Web of Science ®Google Scholar
• Yang W, Shen J, Wu M et al. Repression of transcription of the p27(Kip1) cyclin-dependent kinase inhibitor gene by c-Myc. Oncogene20(14), 1688–1702 (2001).
   PubMed Web of Science ®Google Scholar
• Seoane J, Le HV, Massague J. Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature419(6908), 729–734 (2002).
   PubMed Web of Science ®Google Scholar
• Staller P, Peukert K, Kiermaier A et al. Repression of p15INK4b expression by Myc through association with Miz-1. Nat. Cell. Biol.3(4), 392–399 (2001).
   PubMed Web of Science ®Google Scholar
• Galaktionov K, Chen X, Beach D. Cdc25 cell-cycle phosphatase as a target of c-myc. Nature382(6591), 511–517 (1996).
   PubMed Web of Science ®Google Scholar
• Coller HA, Grandori C, Tamayo P et al. Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion. Proc. Natl Acad. Sci. USA97(7), 3260–3265 (2000).
   PubMed Web of Science ®Google Scholar
• Strieder V, Lutz W. E2F proteins regulate MYCN expression in neuroblastomas. J. Biol. Chem.278(5), 2983–2989 (2003).
   PubMedGoogle Scholar
• De los Santos M, Zambrano A, Aranda A. Combined effects of retinoic acid and histone deacetylase inhibitors on human neuroblastoma SH-SY5Y cells. Mol. Cancer Ther.6(4), 1425–1432 (2007).
   PubMed Web of Science ®Google Scholar
• Cheung B, Hocker JE, Smith SA, Norris MD, Haber M, Marshall GM. Favorable prognostic significance of high-level retinoic acid receptor β expression in neuroblastoma mediated by effects on cell cycle regulation. Oncogene17(6), 751–759 (1998).
   PubMedGoogle Scholar
• Villani MG, Appierto V, Cavadini E et al. 4-oxo-fenretinide, a recently identified fenretinide metabolite, induces marked G2-M cell cycle arrest and apoptosis in fenretinide-sensitive and fenretinide-resistant cell lines. Cancer Res.66(6), 3238–3247 (2006).
   PubMed Web of Science ®Google Scholar
• Yuza Y, Agawa M. Gene and protein expression profiling during differentiation of neuroblastoma cells triggered by 13-cis retinoic acid. J. Pediatr. Hematol. Oncol.25(9), 715–720 (2003).
   PubMed Web of Science ®Google Scholar
• Reynolds CP, Wang Y, Melton LJ, Einhorn PA, Slamon DJ, Maurer BJ. Retinoic-acid-resistant neuroblastoma cell lines show altered MYC regulation and high sensitivity to fenretinide. Med. Pediatr. Oncol.35(6), 597–602 (2000).
   PubMedGoogle Scholar
• Silchenko A, Tass P. Computational modeling of paroxysmal depolarization shifts in neurons induced by the glutamate release from astrocytes. Biol. Cybern.98(1), 61–74 (2008).
   PubMedGoogle Scholar
• Chan HS, Gaille BL, DeBoer G et al.MYCN protein expression as a predictor of neuroblastoma prognosis. Clin. Cancer Res.3(10), 1699–1706 (1997).
   PubMed Web of Science ®Google Scholar
• Bordow SB, Norris MD, Haber PS, Marshall GM, Haber M. Prognostic significance of MYCN oncogene expression in childhood neuroblastoma. J. Clin. Oncol.16(10), 3286–3294 (1998).
   PubMedGoogle Scholar
• Cohn SL, London WB, Haung D et al. MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN. J. Clin. Oncol.18(21), 3604–3613 (2000).
   PubMedGoogle Scholar
• de Jong H. Modeling and simulation of genetic regulatory systems: a literature review. J. Computat. Biol.9(1), 67–103 (2002).
   PubMed Web of Science ®Google Scholar
• Ashyraliyev M, Fornekong-Nanfack Y, Kaandrop JA, Blom JG. Systems biology: parameter estimation for biochemical models. FEBS J.276(4), 886–902 (2009).
   PubMedGoogle Scholar
• Needham CJ, Bradford JR, Bulpitt AJ, Westhead DR. A primer on learning in Bayesian networks for computational biology. PLoS Comput. Biol.3(8), e129 (2007).
   Google Scholar
• Venancio TM, Aravind L. Reconstructing prokaryotic transcriptional regulatory networks: lessons from actinobacteria. J. Biol.8(3), 29 (2009).
   PubMedGoogle Scholar
• Herrgard MJ, Swainston N, Dobson P et al. A consensus yeast metabolic network reconstruction obtained from a community approach to systems biology. Nat. Biotech.26(10), 1155–1160 (2008).
   PubMedGoogle Scholar
• Ideker T, Thorsson V, Ranish JA et al. Integrated genomic and proteomic analyses of a systematically perturbed metabolic network. Science292(5518), 929–934 (2001).
   PubMed Web of Science ®Google Scholar
• Chang WC, Li CW, Chen BS. Quantitative inference of dynamic regulatory pathways via microarray data. BMC Bioinformatics6, 44 (2005).
   PubMedGoogle Scholar
• Edgar D, Kenny S, Almond S, Murray P. Topography, stem cell behaviour, and organogenesis. Pediatr. Surg. Int.20(10), 737–740 (2004).
   PubMedGoogle Scholar
• Brandman O, Meyer T. Feedback loops shape cellular signals in space and time. Science322(5900), 390–395 (2008).
   PubMedGoogle Scholar
• Ankers JM, Spiller DG, White MR, Harper CV. Spatio – temporal protein dynamics in single living cells. Curr. Opin. Biotechnol.19(4), 375–380 (2008).
   PubMedGoogle Scholar
• Werner S, Krieg T, Smola H. Keratinocyte – fibroblast interactions in wound healing. J. Invest. Dermatol.127(5), 998–1008 (2007).
   PubMed Web of Science ®Google Scholar
• Fellin T. Communication between neurons and astrocytes: relevance to the modulation of synaptic and network activity. J. Neurochem.108(3), 533–544 (2009).
   PubMed Web of Science ®Google Scholar
• Ruff RL. Neurophysiology of the neuromuscular junction: overview. Ann. NY Acad. Sci.998, 1–10 (2003).
   PubMedGoogle Scholar
• Sell H, Dietze-Schroeder D, Eckel J. The adipocyte–myocyte axis in insulin resistance. Trends Endocrinol. Metab.17(10), 416–422 (2006).
   PubMed Web of Science ®Google Scholar
• Fernandez-Gonzalez R, Barcellos-Hoff MH, Ortiz-de-Solorzano C. A tool for the quantitative spatial analysis of complex cellular systems. IEEE Trans. Image Process.14(9), 1300–1313 (2005).
   PubMedGoogle Scholar
• Wu FT, Stefanini MO, MacGabhann F, Popel AS. A compartment model of VEGF distribution in humans in the presence of soluble VEGF receptor-1 acting as a ligand trap. PLoS ONE4(4), e5108 (2009).
   Google Scholar
• Lander ES, Linton LM, Birren B et al. Initial sequencing and analysis of the human genome. Nature409(6822), 860–921 (2001).
   Google Scholar
• International_HapMap_Consortium. The International HapMap Project. Nature426(6968), 789–796 (2003).
   PubMed Web of Science ®Google Scholar
• Auer H, Newsom DL, Kornacker K. Expression profiling using Affymetrix GeneChip microarrays. Methods Mol. Biol.509, 35–46 (2009).
   PubMedGoogle Scholar
• Matsumura H, Krüger DH, Kahl G, Terauchi R. SuperSAGE: a modern platform for genome-wide quantitative transcript profiling. Curr. Pharm. Biotechnol.9(5), 368–374 (2008).
   PubMedGoogle Scholar
• Desiere F. Towards a systems biology understanding of human health: interplay between genotype, environment and nutrition. Biotechnol. Annu. Rev.10, 51–84 (2004).
   PubMedGoogle Scholar
• Mariman EC. Nutrigenomics and nutrigenetics: the ‘omics’ revolution in nutritional science. Biotechnol. Appl. Biochem.44(Pt 3), 119–128 (2006).
   PubMedGoogle Scholar
• Robles TF, Kiecolt-Glaser JK. The physiology of marriage: pathways to health. Physiol. Behav.79(3), 409–416 (2003).
   PubMed Web of Science ®Google Scholar
• Varki A, Geschwind DH, Eichler EE. Explaining human uniqueness: genome interactions with environment, behaviour and culture. Nat. Rev. Genet.9(10), 749–763 (2008).
   PubMed Web of Science ®Google Scholar
• Knutsson A. Health disorders of shift workers. Occup. Med. (Lond.)53(2), 103–108 (2003).
   Google Scholar
• Cole SW, Hawkley LC, Arevalo JM, Sung CY, Rose RM, Cacioppo JT. Social regulation of gene expression in human leukocytes. Genome Biol.8(9), R189 (2007).
   PubMed Web of Science ®Google Scholar
• Brazma A, Hingamp P, Quackenbush J et al. Minimum information about a microarray experiment (MIAME) – toward standards for microarray data. Nat. Genet.29(4), 365–371 (2001).
   PubMed Web of Science ®Google Scholar
• Bustin SA, Benes V, Garson JA et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin. Chem.55(4), 611–622 (2009).
   PubMed Web of Science ®Google Scholar
• Hucka M, Finney A, Bornsteiin BJ et al. Evolving a lingua franca and associated software infrastructure for computational systems biology: the Systems Biology Markup Language (SBML) project. Syst. Biol. (Stevenage)1(1), 41–53 (2004).
   PubMedGoogle Scholar
• Hunter PJ. The IUPS Physiome Project: a framework for computational physiology. Prog. Biophys. Mol. Biol.85(2–3), 551–569 (2004).
   PubMedGoogle Scholar
• Bilke S, Chen QR, Westerman F, Schwab M, Catchpoole D, Khan J. Inferring a tumor progression model for neuroblastoma from genomic data. J. Clin. Oncol.23(29), 7322–7331 (2005).
   PubMedGoogle Scholar
• Panetta JC, Schaiquevich P, Santana VM, Stewart CF. Using pharmacokinetic and pharmacodynamic modeling and simulation to evaluate importance of schedule in topotecan therapy for pediatric neuroblastoma. Clin. Cancer Res.14(1), 318–325 (2008).
   PubMedGoogle Scholar
• Hunsberger S, Albert PS, London WB. A finite mixture survival model to characterize risk groups of neuroblastoma. Stat. Med.28(8), 1301–1314 (2009).
   PubMedGoogle Scholar